Chi Zuo Hua, Wei Wei, Bu Ding Fang, Li Huan Huan, Ding Fei, Zhu Ping
The First Affiliated Hospital/School of Clinical Medicine, Guang Dong Pharmaceutical University, Guangzhou.
Kangso Medical Inspection.
Medicine (Baltimore). 2018 Oct;97(40):e12695. doi: 10.1097/MD.0000000000012695.
The aim of this study was to investigate the usefulness of targeted high-throughput sequencing (HTS) for the molecular diagnosis of primary immunodeficiency diseases (PID).A total of 56 clinically diagnosed or suspected PID patients were divided into 4 groups according to the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 and their chief clinical presentations. Patients and their biological family members were examined by targeted HTS, which sequenced the exons and ±10 bp flanking introns of 171 PID-related genes panel. All significant variants were confirmed by PCR-Sanger sequencing. Pathogenicity of the variants was evaluated by using bioinformatics.A total of 117 variants in 73 genes were found in 56 patients. Accurate molecular diagnosis of PID was made in 13 (23.2%) patients, and 12 novel mutations were detected in these patients. Twenty-seven patients carried heterozygous variants that are probably pathogenic in ≥2 genes; 16 patients had only 1 missense variant, or had several variants but not >1 variant was deleterious as evaluated by bioinformatics. The meaning of the targeted HTS results of these patients remains to be studied.Targeted HTS can make a precise molecular diagnosis of PID and detect more novel pathogenic mutations. More and more variations with ambiguous significance are discovered and explanation of these variations is a challenge to the clinicians.
本研究的目的是探讨靶向高通量测序(HTS)在原发性免疫缺陷病(PID)分子诊断中的实用性。根据国际免疫学会联盟原发性免疫缺陷专家委员会2015年的标准及其主要临床表现,将56例临床诊断或疑似PID患者分为4组。对患者及其生物学家庭成员进行靶向HTS检测,该检测对171个PID相关基因面板的外显子及内含子侧翼±10 bp区域进行测序。所有显著变异均通过PCR-Sanger测序进行确认。使用生物信息学评估变异的致病性。56例患者中共发现73个基因的117个变异。13例(23.2%)患者得到了PID的准确分子诊断,且在这些患者中检测到12个新突变。27例患者携带可能在≥2个基因中致病的杂合变异;16例患者仅有1个错义变异,或有多个变异,但经生物信息学评估有害变异不超过1个。这些患者靶向HTS结果的意义仍有待研究。靶向HTS能够对PID进行精确的分子诊断,并检测到更多新的致病突变。越来越多意义不明确的变异被发现,对这些变异的解释对临床医生来说是一项挑战。